（来源：千龙网） 出台专项支持政策、搭建关键共性服务平台、营造产业生态……以微元合成为代表，昌平区的合成生物 制造产业规模正在加速扩展。截至目前，落户昌平的合成生物制造企业数量为146家。在生物基新材 料、胶原蛋白、生物育种、气体发酵等合成生物制造细分领域，均有企业持续深耕。 目前，昌平合成生物制造产业已经进入集群化发展新阶段。昌平区相关负责人透露了新年新目标：2026 年，昌平区力争新落地10个合成生物制造标志性项目，实现合成生物制造产业收入突破100亿元。接下 来，昌平区将从区域领先迈向全国引领，逐渐形成重要影响力和号召力，打造合成生物制造创新策源地 和产业引领区。 春节假期刚过，在未来科学城合成生物制造产业创新孵化区及转化加速区内，一批微生物"工人"已经开 工，不知疲倦地高效产出阿洛酮糖、饲料蛋白等"生物造"产品。与2025年同期相比，在北京昌平区落户 的合成生物制造企业数量增长近七成，产业规模持续壮大，集聚效应日益凸显。 从实验室里的毫克级样品，到工业生产线上的吨级产品，园区内，微元合成生物技术（北京）有限公司 已成功实现甘露醇、阿洛酮糖、木糖醇等产品的商业化落地，聚焦人类营养、动物营养、日化原料、药 ...

走进实验室，整齐排列的一个个生物反应器，就是一座座"无声工厂"，肉眼不可见的微生物作为"新型 工人"，一呼一吸之间就能生产各类合成生物产品，堪称"生物造万物"。刘波介绍，最近，"新型工 人"的研发也在持续进行，公司菌种库内保存的微生物样本已达十余万种，随着研发的推进，这个数字 仍在不断增长。 出台专项支持政策、搭建关键共性服务平台、营造产业生态……以微元合成为代表，昌平区的合成生物 制造产业规模正在加速扩展。截至目前，落户昌平的合成生物制造企业数量为146家。在生物基新材 料、胶原蛋白、生物育种、气体发酵等合成生物制造细分领域，均有企业持续深耕。 目前，昌平合成生物制造产业已经进入集群化发展新阶段。昌平区相关负责人透露了新年新目标：2026 年，昌平区力争新落地10个合成生物制造标志性项目，实现合成生物制造产业收入突破100亿元。接下 来，昌平区将从区域领先迈向全国引领，逐渐形成重要影响力和号召力，打造合成生物制造创新策源地 和产业引领区。 本报讯（记者 刘苏雅）春节假期刚过，在未来科学城合成生物制造产业创新孵化区及转化加速区内， 一批微生物"工人"已经开工，不知疲倦地高效产出阿洛酮糖、饲料蛋白等"生物造"产 ...

Core Viewpoint - "Micro Yuan Synthesis" has recently secured nearly 300 million yuan in a new round of equity financing, with the funds primarily aimed at accelerating the research and development of methanol-based bio-manufacturing of bulk bio-based products [1][2]. Group 1: Company Developments - "Micro Yuan Synthesis" has successfully developed and industrialized several human and animal nutrition products, including allulose, lutein, and mannitol [1]. - The company has achieved significant commercial progress in the development of core products like allulose, becoming the first in China to receive administrative approval for allulose production through a biological fermentation process [1][2]. - A strategic partnership has been established with Cargill, focusing on the promotion and production collaboration of allulose and other sugar-reducing products [2]. Group 2: Industry Context - The global production of chemical products is approximately 2.3 billion tons annually, while bio-based products account for only 180 million tons, indicating a significant gap and potential for growth in bio-manufacturing [4]. - The development of non-grain bio-based products is essential, particularly using alternative carbon sources like straw and CO2, to address the challenges of raw material costs in bio-manufacturing [4]. - Methanol is identified as an ideal alternative carbon source, with China's coal-based methanol production capacity exceeding 10 million tons, representing 67% of the global total, and facing overcapacity issues [4].

Core Viewpoint - Sanwei Biotech is actively advancing the industrialization and market expansion of diversified products, including allulose, tagatose, mannitol, and others, to enhance its product structure and overall business resilience [2]. Product Development - Allulose: The company has launched a production capacity of 10,000 tons, with an additional 10,000 tons under construction. Sales from January to September have shown significant year-on-year growth, meeting the needs of domestic clients like Nayuki Tea and steadily increasing overseas demand [2]. - Tagatose: Approved as a new food ingredient in China since 2014 and recognized in multiple countries, the company is optimizing production processes to reduce costs and enhance market potential. Tagatose and allulose both possess health benefits related to blood sugar control and gut microbiota regulation, with ongoing efficacy research in collaboration with Binzhou Medical University [2]. - Mannose: The company has small-scale production capabilities and is in the process of applying for domestic and overseas certifications. Mannose is gaining attention for its applications in medical research and health nutrition [2]. - Mannitol: The company has developed a cost advantage through new production processes and plans to gradually introduce it to the market [2]. - Reb M: The market acceptance of Reb M is increasing through continuous promotion, and the company has also developed sweet tea glycosides from regular steviol glycosides, with mature processing technology [2]. - Cosmetic Ingredients: The company leverages its synthetic biology technology to develop glycerol glycosides, ascorbic acid glucosides, and alpha arbutin, expanding its product applications in the daily chemical sector [2]. Strategic Goals - The gradual advancement of these products will help the company maintain its core competitiveness in erythritol while enhancing product diversity and improving overall business stability and risk resistance [2].

Core Viewpoint - Zhejiang Huakang Pharmaceutical Co., Ltd. is undergoing a significant acquisition involving the issuance of shares and cash payment to purchase assets, specifically in the functional sugar alcohol sector, which is experiencing steady market growth and consolidation [1][2]. Group 1: Market Overview - The functional sugar alcohol market in China has shown steady growth, with the market size reaching approximately 10.2 billion yuan in 2022 and projected to grow to 21 billion yuan by 2027, indicating substantial growth potential [5]. - The global functional sugar alcohol market was estimated at 4.6 billion USD in 2022, with expectations to reach 7.7 billion USD by 2030, reflecting a compound annual growth rate (CAGR) of about 6.7% [5]. - The xylitol market in China has also been expanding, with the global market projected to grow from 1.12 billion USD in 2024 to 1.64 billion USD by 2029, at a CAGR of 7.9% [7]. Group 2: Company Position and Strategy - Huakang and the target company are leading players in the xylitol production sector, with significant market shares and competitive advantages in production capacity and technology [4][11]. - The acquisition aims to consolidate Huakang's position in the domestic and international xylitol market, enhancing operational efficiency and resource integration across supply chains, production, and sales channels [11][13]. - The target company has a production capacity of 20,000 tons of xylitol, and Huakang has a capacity of 35,000 tons, positioning both companies as major suppliers in the industry [9][10]. Group 3: Financial Aspects of the Transaction - The total cash consideration for the acquisition is 366 million yuan, to be paid in two installments: 244 million yuan within 30 days post-registration and 122 million yuan within 30 days after the first payment's one-year anniversary [19][20]. - The cash payment structure is designed to ensure transaction certainty while alleviating short-term cash flow pressures for Huakang, allowing for better financial management [20][22]. - The acquisition is expected to generate goodwill of approximately 46.71 million yuan, with the total goodwill post-transaction reaching 813.30 million yuan, representing 20.54% of Huakang's net assets [23].

Core Insights - The inter-provincial alliance led by Sichuan has officially announced the results of its bulk purchasing initiative, with 376 product specifications from 241 pharmaceutical companies selected, some prices dropping over 98%, setting new national low price records [1] - This procurement action signifies the normalization of the bulk purchasing model and accelerates the "volume-for-price" logic in the pharmaceutical industry [1] Price Drop - 30 product varieties have set new national low prices, with the price of inosine injection dropping over 91% [2] - For instance, the price of inosine injection (2ml: 0.1g) from Beite Pharmaceutical fell from 11.36 yuan to 0.98 yuan per unit, a decrease of 91% [2] - Notably, Changle Pharmaceutical reported a "floor price" of 0.63 yuan per unit for inosine injection, a 30% reduction from its original price, marking the lowest price in the event [2] Rule Analysis - The core rule of this procurement is the "external provincial minimum price linkage," where companies can be selected if their quoted price does not exceed 1.8 times the lowest selected price from other provinces [3] - This mechanism has led to a price war, with companies forced to collectively lower prices, as seen in the case of inosine injection where 51 companies competed, leaving only a few survivors [3] Competitive Landscape - The procurement attracted 413 companies, with only 241 selected, resulting in a dropout rate of over 40% [4] - Leading companies like Kelun Pharmaceutical and China National Pharmaceutical Group leveraged their scale advantages to secure multiple product specifications, while smaller firms face tough choices between "price reduction for volume" or "abandoning bids" [4] Model Innovation - The Sichuan alliance's procurement is not an isolated case; following Beijing's lead in 2022, other regions like Tianjin and Guangdong have adopted similar "volume linkage" models, creating a national trend [5] - The National Healthcare Security Administration has encouraged such models in 2023, aiming to accelerate the equalization of prices for already collected varieties [5] Industry Transformation - The normalization of bulk purchasing is reshaping the industry ecosystem [6] - Price transparency is enforced through the external provincial minimum price linkage, compelling companies to unify their national pricing systems [6] - Leading companies are capturing market share due to cost advantages, while smaller firms face pressure to either transform or exit the market [6] Future Outlook - The bulk purchasing model is extending from pharmaceuticals to medical consumables, with Guangdong recently releasing a draft for bulk purchasing of high-value consumables [7] - As more categories and regions join, a "price linkage network" under a unified national market will accelerate, continuing the trend of "volume-for-price" in the pharmaceutical industry [7] Conclusion - The shift from "squeezing profits" to "establishing mechanisms" in bulk purchasing is becoming a key driver for deepening medical reform [9] - The convergence of price transparency and supply scale may lead to a new round of industry reshuffling, where only companies that focus on clinical value and cost advantages can survive [9]